CLINICAL TRIAL: Quad Therapy Using a Checkpoint Inhibitor with Daratumumab in Relapsed/Refractory Myeloma

Later this month (July 2016), Celgene will be opening a Phase 1/2 study for approximately 406 relapsed/refractory myeloma patients using the following drugs to actively treat disease: Dararatumumab dexamethasone Durvalumab Pomalidomide Eligibility criteria includes:

• measurable disease as defined by m-protein or serum free light chains
• must have failed last line of treatment (refractory to last line of treatment).
• must have achieved at least a minimal response to at least one prior anti-myeloma regimen before relapse

For more information on this clinical trial, click on the SparkCures box below: SparkCures Clinical Trial: Durvalumab & Daratumumab